Clinical pharmacokinetics of docetaxel : recent developments

Clinical Pharmacokinetics
Sharyn D BakerJaap Verweij

Abstract

Docetaxel belongs to the class of taxane antineoplastic agents that act by inducing microtubular stability and disrupting the dynamics of the microtubular network. The drug has shown a broad spectrum of antitumour activity in preclinical models as well as clinically, with responses observed in various disease types, including advanced breast cancer and non-small cell lung cancer. The pharmacokinetics and metabolism of docetaxel are extremely complex and have been the subject of intensive investigation in recent years. Docetaxel is subject to extensive metabolic conversion by the cytochrome P450 (CYP) 3A isoenzymes, which results in several pharmacologically inactive oxidation products. Elimination routes of docetaxel are also dependent on the presence of drug-transporting proteins, notably P-glycoprotein, present on the bile canalicular membrane. The various processes mediating drug elimination, either through metabolic breakdown or excretion, impact substantially on interindividual variability in drug handling. Strategies to individualise docetaxel administration schedules based on phenotypic or genotype-dependent differences in CYP3A expression are underway and may ultimately lead to more selective chemotherapeutic use of thi...Continue Reading

References

Feb 20, 1991·Journal of the National Cancer Institute·I Ringel, S B Horwitz
Apr 1, 1996·Journal of Pharmacokinetics and Biopharmaceutics·R BrunoL B Sheiner
Jan 1, 1996·Investigational New Drugs·S UrienJ P Tillement
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G LiuE Warner
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·A SparreboomO van Tellingen
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J MillwardC Blanc
Jun 6, 1997·Journal of Chromatography. B, Biomedical Sciences and Applications·W J LoosA Sparreboom
Aug 15, 1997·Journal of Chromatography. B, Biomedical Sciences and Applications·H RosingJ H Beijnen
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R BrunoL B Sheiner
Aug 8, 1998·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·J Van AsperenJ H Beijnen
Aug 8, 1998·Clinical Pharmacology and Therapeutics·D Wagner
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D P PetrylakC A Olsson
Mar 27, 1999·Clinical Pharmacokinetics·S J Clarke, L P Rivory
Sep 24, 1999·Journal of the National Cancer Institute·B AmirimaniT R Rebbeck
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M EspositoR Rosso
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A AdjeiC Erlichman
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N YamamotoN Saijo
Sep 7, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A LortholaryE Gamelin
Sep 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W C ZamboniK H Tkaczuk
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H OzerUNKNOWN American Society of Clinical Oncology
Nov 22, 2000·Journal of Chromatography. B, Biomedical Sciences and Applications·M B Garg, S P Ackland
Jan 4, 2001·Cancer Chemotherapy and Pharmacology·K H TkaczukD A Van Echo
Feb 17, 2001·Clinical Pharmacology and Therapeutics·C Veyrat-FolletP Chaikin
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M M MalingréJ H Schellens
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M AndoN Katsumata
Feb 24, 2001·Bioorganic & Medicinal Chemistry Letters·S IimuraT Soga
Jun 8, 2001·Investigational New Drugs·M M MalingréJ H Schellens
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Aug 14, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·J CiccoliniA Durand
Aug 16, 2001·Journal of the National Cancer Institute·M R VredenburgR J Bernacki
Dec 12, 2001·Pharmacogenetics·E HustertL Wojnowski
Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M LouwerensR de Wit
Mar 12, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G LunardiM Esposito
May 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L van ZuylenJ Verweij
Jul 11, 2002·Cancer Chemotherapy and Pharmacology·Pierre MarchettiniPaul H Sugarbaker

❮ Previous
Next ❯

Citations

Sep 22, 2006·Cancer Chemotherapy and Pharmacology·Angelo MancinelliM Calvani
Apr 10, 2013·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Ping DuYuankai Shi
Feb 17, 2010·The Pharmacogenomics Journal·H EdvardsenV N Kristensen
Nov 29, 2012·Pharmacogenetics and Genomics·Lionel D LewisUNKNOWN Alliance for Clinical Trials in Oncology
Jun 20, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne-Joy M de GraanAlex Sparreboom
Aug 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lionel D Lewis, Mark J Ratain
Feb 4, 2014·Cancer Chemotherapy and Pharmacology·Michelle A RudekJohn F Deeken
Sep 27, 2013·Clinical Pharmacokinetics·Andrew K L GoeyJan H M Schellens
Apr 14, 2010·Expert Opinion on Investigational Drugs·Raffaele LongoGiampietro Gasparini
May 13, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Joo Hyun LeeYoung-Joo Lee
May 30, 2008·Clinical Pharmacology and Therapeutics·S D BakerA Sparreboom
May 20, 2008·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ron H N van Schaik
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ryan M FrankeAlex Sparreboom
Jun 21, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia M LoRussoHoward A Burris
Jul 7, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dominique VodovarFrédéric Pène
Sep 10, 2015·Journal of Pharmaceutical and Biomedical Analysis·Raül Rigo-BonninPedro Alía
May 30, 2017·Acta Pharmacologica Sinica·Xin-Shuai WangYuan-Pei Li
May 31, 2017·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Rafid Salim JabirJohnson Stanslas
Dec 23, 2008·Advanced Drug Delivery Reviews·Sharon Marsh, Geoffrey Liu
May 16, 2014·International Journal of Cancer. Journal International Du Cancer·Dilek IusufAlfred H Schinkel
Mar 8, 2014·Andrologia·R AltintasA Beytur
Jun 27, 2017·The Prostate·Megan Crumbaker, Howard Gurney
Feb 12, 2017·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Tianyun HaoShuai Qian
Apr 28, 2018·Critical Reviews in Analytical Chemistry·Gilmar Hanck da SilvaMarlus Chorilli
Dec 19, 2017·Expert Opinion on Drug Metabolism & Toxicology·Sang Hoon LeeHyo-Kyung Han
Jun 28, 2007·British Journal of Cancer·F PuissetE Chatelut
Oct 13, 2017·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Amy LyLaura Alwan
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Robert A B van WaterschootAlfred H Schinkel
Jan 9, 2014·British Journal of Cancer·S HuA Sparreboom
Dec 11, 2008·Analytical and Bioanalytical Chemistry·Christina L RandallDavid H Gracias

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Pharmacokinetics
Stephen J Clarke, Laurent P Rivory
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Bernard J KomoroskiRaman Venkataramanan
Toxicology in Vitro : an International Journal Published in Association with BIBRA
Nicola F SmithAlex Sparreboom
© 2021 Meta ULC. All rights reserved